TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fluorescence uptake at the area of cystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Training Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Proven/Probable/Possible Fungal Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Improvement (CGI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hamilton Rating Scale for Depression (HRSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center for Epidemiological Studies - Depression Scale (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak Expiratory Flow (PEF) variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sound quality rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of 200 mg Vorinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of 400 mg Vorinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Tear Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Circulating Prostate Cells (CPCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of Final Device Tip Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Final Device Path (Vector)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation Doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRM positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global quality of life at two years post surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: progress free time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of CP-690,550
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of TDCS treatment
Endpoint domain: Adverse events/effects
Primary endpoint: ghrelin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: dyspepsia subtype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cambridge Depersonalization Scale (CDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the curve for prediction models
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Assessment of Functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Clinically Significant Abnormal Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy cardiac distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DPICS-IV Observed Parenting Skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: DPICS-IV Observational Coding During Clean Up Situation Task
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Stop Signal Task: Increased Parent Inhibitory Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional outcome range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Procedural Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correlation between Central Venous Pressure (CVP) and Internal Jugular Vein (IJV) distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in SAPS-PD Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rates after CPR
Endpoint domain: Mortality/survival
Primary endpoint: VAS Score at 1 Hour at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS Score at 1 Hour With Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS Score at 24 Hours at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS Score at 24 Hours With Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS Score at 48 Hours at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS Score at 48 Hours With Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Resolution of Angioedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure flow urodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in the combined reflective TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative dose reduction of ICS or OCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Alive and Free of Progression at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: pO2 levels in rectal cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urge-to-cough sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive/negative cough response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in HDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of diabetes mellitus (DM)/impaired glucose tolerance (IGT)/insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Surface resting EMG activity of the upper trapezius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AUC0-inf of midazolam IV and S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of omeprazole to 5-hydroxyomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 0-12 hr urinary molar ratio of caffeine metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 0-12 hr urinary dextromethorphan/dextrorphan ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Disease Activity Score of 28 joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) Status
Endpoint domain: Mortality/survival
Primary endpoint: Renal functional decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in PUFAs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effective Lens Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in couple functioning and stability
Endpoint domain: Life impact
Endpoint subdomain: Relationship functioning
Primary endpoint: Unprotected Sex Acts
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 24-h average systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Jousse-Joulin ultrasonography score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With SHP648 Related Serious and Non- Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Met the Efficacy Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first occurrence of a serious adverse event of malignancy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pharmacokinetics (PK) of ASA404
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: multi-lineage hematopoietic chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum concentration (Cmax) of Biolimus A9TM and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-maximum concentration (Tmax) of Biolimus A9TM and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of AEs (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: T-cell changes in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean mitral valve gradient at peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 2-year Overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability at the MTD
Endpoint domain: Adverse events/effects
Primary endpoint: Speech perception scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL particle size and density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High frequency of Heart Rate Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Tetanus Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Diphtheria Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration of Antibody to Pertussis Antigens Pre- and Post-Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hemodynamic instability score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported physical disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnosis of post-transplant diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Phone Book Search (PBS) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Supermarket Receipt (SupRe) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Book Reading (BR) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cellular message (CM) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cellular Entry Search (CES) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reading Computer Screen (RCS) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of Participants Who Had Experienced Either Acute ([>or=] Grade II) or Chronic Graft Versus Host Disease (GVHD) by Month 24
Endpoint domain: Adverse events/effects
Primary endpoint: maximum voluntary isometric strength of knee extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced pain post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until Ileus resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of occult CNS localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Creatine synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in nightmare frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Responders at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-phase insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adverse Events relating to the procedure and device
Endpoint domain: Adverse events/effects
Primary endpoint: lung function after allergen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean sitting Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of biomarkers (PTX3 and VEGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of biomarkers (PTX3 and VEGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of biomarkers (PTX3 and VEGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of biomarkers (PTX3 and VEGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use of the New Genotropin Mark VII Injection Pen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: curative resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline 24-hour Urinary Free Cortisol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Immunoglobulin levels in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Macroscopic anatomic malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: fractional sodium excretion (percent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary sodium/urinary creatinin (mmol/mmol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fractional Chloride excretion (percent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Antibody Titer to HPV 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Titer to HPV 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Titer to HPV 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Titer to HPV 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nosocomial urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Success at Day 180: Percent of Responders
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: intra-hepatic lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin mediated glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Days to regression of jaundice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in anatomical dead space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in ventilatory efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in exercise tolerance during walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number/proportion of sex partners disclosed
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Response Rate (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: High Contrast Time-Controlled Visual Acuity (TCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV RNA quantitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Low Anterior Resection Syndrome Score (LARS score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients maintained on medical treatment with lanreotide Autogel
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients receiving other medical treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood concentrations of active ingredients and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantity of concomitant medications used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Types of concomitant medications used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in intrahepatic triglyceride (IHTG) content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat Mass Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle Mass Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visceral Fat Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lens Fit - Decentration After Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Fit - Tightness After Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Fit - Post-Blink Lens Movement After Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Sodium Blood Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change Potassium Blood Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 2 Hours Plasma Glucose (2-h PG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Failure-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in Reflux Symptom Index Score (RSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical Global Impression -- Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Alzheimer's Disease Assessment Scale (ADAS-JCog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of patients reaching ASAS20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight for height Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endothelial Dependent Mediated Vascular Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in WOMAC A1 Subscore (Walking Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neurodevelopmental Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in baby's latch at the breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of retinal vascular Plexus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived wellbeing levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrent asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score on Visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggressive Acts
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of pathogenic autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Enhancement of the Liver and Blood Vessels Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Plasma Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in apnea-hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Performance of activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete Tumor Necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Adherence to Mediterranean diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in obsessive and compulsive symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of death or myocardial infarction from CV causes, TVR, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Overall Rate of Response (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes